This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus repositioning of proprietary shelved assets remain distinct, each with their unique opportunities and challenges, much of the underlying big data content and computational approaches used to identify lead assets in a given therapeutic area of interest remain constant. This talk will provide a high level overview of some of the tools we have deployed to identify new uses of existing drugs. A couple of use cases will be presented describing the specific use of chemogenomics and systems biology methodologies to identify new drugs/targets in Inflammatory Bowel Disease and Psoriasis.